Ingrid Mayer
Clinical Mentor to Alex Pfannenstein · Vanderbilt Univ Sch of Med
Credentials: · ·
History
Present
- 2001–2004
Hematology and Medical Oncology
- 1998–2001
Internal Medicine
- 1994–1998
Doctor of Medicine
Research
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Review · Nature Reviews Clinical Oncology · 2016 · 2,314 citations
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
New England Journal of Medicine · 2019 · 2,067 citations
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
New England Journal of Medicine · 2018 · 1,827 citations
36 papers
36 papers
21 papers
- AW
19 papers
19 papers
18 papers
17 papers
16 papers
Grants
- 1998–2025
National Cancer Institute · P30
Project lead · $178.9K · Vanderbilt University Medical Center
- 2003–2024
National Cancer Institute · P50
PI · $9.4M · Vanderbilt University Medical Center
- 2009–2014
Targeted Therapies in Breast Cancer
National Cancer Institute · K23
Contact PI · $819.7K · Vanderbilt University
Clinical trials
- 2018–2020
Principal investigator · Terminated · Phase 1, Phase 2
Vanderbilt-Ingram Cancer Center
- 2015–2031
Principal investigator · Active not recruiting · Phase 3
ECOG-ACRIN Cancer Research Group
- 2010–2016
Principal investigator · Completed · Phase 1
Vanderbilt-Ingram Cancer Center
- 2010–2011
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
Principal investigator · Terminated · Phase 2
Vanderbilt-Ingram Cancer Center